The cGAS-STING pathway — DNA in the wrong place and the inflammaging it triggers

The basic logic is elegant. Your cell's nucleus contains DNA. Cytoplasm does not, under normal healthy conditions, contain DNA. When double-stranded DNA appears in the cytosol, it signals something has gone wrong — either a DNA virus has injected genetic material into the cell, or cellular damage has allowed nuclear or mitochondrial DNA to leak out of its compartment. cGAS is the sensor. It sits in the cytoplasm, encounters cytoplasmic dsDNA, and uses it as a template to synthesize cGAMP. cGAMP then binds STING, a protein anchored to the endoplasmic reticulum membrane, activating it. Activated STING recruits and activates the kinase TBK1, which phosphorylates the transcription factor IRF3. IRF3 moves to the nucleus and drives transcription of type I interferons — primarily IFN-alpha and IFN-beta — and a broader program of interferon-stimulated genes that put the cell and its neighbors on immune alert. NF-kB is also activated downstream of STING, driving additional inflammatory gene expression. The result is a potent antiviral and pro-inflammatory state.

When a herpes simplex virus injects its DNA into a cell, this is the pathway doing its job. When the cell's own DNA leaks into the wrong compartment, this is the pathway doing its job on the wrong target. And in aging tissue, that second scenario is not rare.

Mitochondria are the primary source of self-DNA activating cGAS in most cellular stress contexts. The mitochondrial genome, as discussed elsewhere in this library, sits adjacent to the electron transport chain in an organelle with limited DNA repair capacity and no histone protection. Damaged mitochondria — through a failure of the membrane permeability transition, through mitophagy defects allowing damaged mitochondria to accumulate, through the process of mitochondrial outer membrane permeabilization — can release mtDNA fragments into the cytosol. cGAS encounters them, cannot distinguish them from viral DNA, and activates STING. This is not a hypothetical sequence. It has been documented in a range of cell types under oxidative stress, in aged tissues in animal models, and in human disease contexts.

Senescent cells contribute a second major source. Cellular senescence — the state in which cells stop dividing, typically because of telomere shortening, DNA damage, or oncogenic stress — is accompanied by the accumulation of cytoplasmic chromatin fragments, pieces of nuclear DNA that, during the process of becoming senescent, spill out of the nucleus into the cytoplasm. These cytoplasmic chromatin fragments are recognized by cGAS and are one of the mechanisms through which senescent cells activate STING and drive the inflammatory output of the senescence-associated secretory phenotype, or SASP. The SASP is not simply a consequence of the cell being damaged; it's partly an active inflammatory program driven, at the molecular level, by the cGAS-STING axis detecting the cell's own displaced chromatin.

Micronuclei — small membrane-enclosed fragments of chromosomal material that form when chromosomes mis-segregate during cell division — also activate cGAS-STING. When the micronuclear envelope ruptures, as it often does, it exposes chromosomal DNA to the cytoplasm. This has been shown to activate STING, contribute to inflammatory signaling, and is one of the mechanisms linking chromosomal instability to chronic inflammation in aging and cancer biology.

The aggregate picture is of a pathway that evolved to defend against pathogens but is chronically activated in aging tissue because aging tissue chronically leaks DNA — from damaged mitochondria, from senescent cells, from chromosomally unstable dividing cells. Each activation drives interferon production and inflammatory gene expression. Sustained over years, in tissue that never fully resolves the underlying damage because the damage is intrinsic to the aging process rather than a discrete infection to be cleared, this becomes a driver of the same low-grade inflammatory state — inflammaging — that underlies atherosclerosis, neurodegeneration, sarcopenia, and a range of other age-associated pathologies.

The clinical evidence for pathological cGAS-STING activation is clearest in a disease called Aicardi-Goutières syndrome. AGS is a rare genetic disorder caused by loss-of-function mutations in DNase enzymes — particularly TREX1, RNASEH2 complex members, SAMHD1, and ADAR1 — that normally degrade cytoplasmic nucleic acids that would otherwise activate cGAS-STING. When those enzymes fail, cytoplasmic DNA accumulates, cGAS-STING is tonically activated, and the result is a devastating inflammatory encephalopathy with features resembling congenital infection. The phenotype of AGS, where a genetic inability to clear cytoplasmic DNA produces severe interferon-driven inflammation affecting the brain, provides a proof of principle that sustained cGAS-STING activation causes disease at the organ level. It also points to the clearance of cytoplasmic DNA as a regulatory process that, when degraded more subtly over years rather than ablated genetically, may contribute to age-associated neuroinflammation.

Systemic lupus erythematosus is another context where cGAS-STING is implicated. Lupus involves autoimmune reactivity against nuclear antigens, and chronic type I interferon production is a hallmark of active disease. Multiple lines of genetic and mechanistic evidence now point to inappropriate cGAS-STING activation — triggered by self-DNA insufficiently cleared by nucleases — as one contributor to the interferon signature of lupus. STING gain-of-function mutations cause a monogenic lupus-like condition called STING-associated vasculopathy with onset in infancy, or SAVI. The lupus-cGAS-STING connection has opened therapeutic interest in STING inhibition as an approach in autoimmune disease.

The connection to senolytics — the class of interventions that clear senescent cells — runs directly through this pathway. Senescent cells activate cGAS-STING. They also resist apoptosis through upregulation of anti-apoptotic proteins, which is part of why they accumulate. Senolytic compounds, including the dasatinib-quercetin combination studied in human trials and navitoclax (ABT-263) in preclinical aging models, work by restoring apoptosis sensitivity in senescent cells, clearing them from tissue. By clearing the cells that activate cGAS-STING via cytoplasmic chromatin fragments, senolytics may reduce cGAS-STING-driven inflammatory output upstream of STING itself. The evidence in human trials for senolytics is still early — the dasatinib-quercetin combination has published results in idiopathic pulmonary fibrosis and diabetic kidney disease, with mixed results, and larger trials are ongoing — but the mechanistic logic connecting senolytic clearance to reduced cGAS-STING activation is sound.

Direct STING modulators are in development. Small-molecule STING inhibitors, including H-151 and related compounds, have shown efficacy in preclinical models of STING-driven inflammatory disease, including models of aging-associated neuroinflammation. None have yet reached clinical approval for aging-related conditions. On the other side of the biology, STING agonists — compounds that deliberately activate STING — are in clinical development as cancer immunotherapies, exploiting the fact that activating innate immune sensing in the tumor microenvironment can drive anti-tumor immune responses. This bidirectionality is worth understanding: the same pathway that drives harmful chronic inflammation in aging tissue is the pathway that, in the context of tumors, can drive beneficial immune recognition. Whether to activate or inhibit cGAS-STING depends entirely on the context.

Mitochondrial protection may represent one of the most upstream intervention points for reducing pathological cGAS-STING activation in aging. If damaged mitochondria leaking mtDNA into the cytoplasm is a primary driver of cGAS activation, then strategies that preserve mitochondrial membrane integrity, enhance mitophagy to clear damaged mitochondria before they rupture, or reduce mitochondrial oxidative stress should reduce the amount of cytoplasmic mtDNA available to activate cGAS. SS-31 / Elamipretide, which stabilizes the inner mitochondrial membrane by binding cardiolipin, has shown effects on mitochondrial membrane permeability in preclinical work consistent with this hypothesis. MOTS-c, by modulating mitochondrial stress responses, may contribute similarly. These connections are mechanistically coherent; whether they translate to measurable reductions in cGAS-STING-driven inflammation in aged humans remains to be demonstrated in adequately powered trials.

What the cGAS-STING story adds to the understanding of aging is a molecular grammar connecting three phenomena that might otherwise seem unrelated: cellular damage, innate immune activation, and chronic inflammation. The grammar reads like this — damage to mitochondria or chromosomes, whether from oxidative stress, telomere dysfunction, genotoxic exposure, or simply the accumulated errors of decades of cell division, releases DNA into places where it isn't supposed to be. A surveillance system built to detect viral invasion detects this misplaced DNA and triggers an alarm. The alarm never resolves because the source of the misplaced DNA — the aging cell's increasing inability to maintain its own compartments — never resolves. The alarm becomes a condition.

The pathway that guards against viruses becomes, in the context of an aging organism, one of the mechanisms by which the body's own cellular damage is converted into chronic inflammation. Identifying that mechanism, precisely, at the molecular level, is what makes cGAS-STING relevant beyond virology. It provides a target — not just for antiviral medicine, not just for autoimmune disease — but for the inflammatory component of aging itself. That target is now being approached from multiple directions simultaneously: from above through senolytic clearance, from within through mitochondrial stabilization, and directly through STING modulators that are still working their way through development. The discovery that began with Chen's lab and a biochemical assay for cytoplasmic DNA sensing has, over about a decade, become one of the organizing frameworks for understanding what aging looks like at the molecular level.

DNA in the wrong place turns out to be more than a cellular accident. It's the signal that drives some of the most consequential chronic inflammation in the aging body. The cell's own past, written in damaged chromosomes and leaking mitochondria, is the message the immune system spends years trying to respond to.